Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Feb 12:11:1345608.
doi: 10.3389/fcvm.2024.1345608. eCollection 2024.

Neuromuscular manifestations of wild type transthyretin amyloidosis: a review and single center's experience

Affiliations
Review

Neuromuscular manifestations of wild type transthyretin amyloidosis: a review and single center's experience

Sasha A Živković et al. Front Cardiovasc Med. .

Abstract

Transthyretin amyloidosis (ATTR) is a condition defined by accumulation of insoluble transthyretin amyloid deposits in multiple organs, especially in the peripheral nerve and heart muscle. ATTR may result from transthyretin mutations (variant ATTR or ATTRv) or may occur with normal transthyretin genotype (wild type ATTR or ATTRwt). ATTRwt was previously known as "senile amyloidosis" and causes cardiomyopathy which may lead to heart failure with a preserved ejection fraction, affecting predominantly elderly men. The exact prevalence of ATTRwt in the general population remains unclear, but its occurrence may be underestimated in women. It was observed that a proportion of ATTRwt cardiomyopathy patients may develop slowly progressing neuropathy that is milder and indolent in comparison with typical progressive neuropathy associated with ATTRv. Furthermore, the causality of neuropathy is often uncertain in patients with ATTRwt. Neuropathy symptoms, including distal sensory loss, unsteadiness and (neuropathic) pain are common in elderly patients with multiple potential causes, and as ATTRwt patients are typically older, relatively high prevalence of peripheral neuropathy is expected with frequent comorbidities. Relatively high prevalence of ATTRwt in elderly population contrasts few documented cases of neuropathy caused by ATTRwt, and there is uncertainty whether ATTRwt neuropathy is an infrequent occurrence or a significant manifestation of multisystemic ATTRwt. We review neurologic and musculoskeletal manifestations of ATTRwt and present clinical features of a single center cohort of ATTRwt patients with suspected peripheral neuropathy.

Keywords: carpal tunnel syndrome; dysautonomia; musculoskeletal disorders (MSD); peripheral neuropathy (PN); transthyretin amyloidosis (ATTR); wild type amyloidosis.

PubMed Disclaimer

Conflict of interest statement

SŽ: Consultancy with Alnylam Pharmaceuticals and Astra Zeneca. PS: Consultancy with Alnylam Pharmaceuticals, Bridgebio, Pfizer, Spectrum Dynamics. The remaining author declares that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Multisystemic manifestations of wild type transthyretin amyloidosis (ATTRwt) in cardiovascular system, peripheral nervous system and connective tissue.

Similar articles

Cited by

References

    1. Liz MA, Coelho T, Bellotti V, Fernandez-Arias MI, Mallaina P, Obici L. A narrative review of the role of transthyretin in health and disease. Neurol Ther. (2020) 9(2):395–402. 10.1007/s40120-020-00217-0 - DOI - PMC - PubMed
    1. Benson MD, Kincaid JC. The molecular biology and clinical features of amyloid neuropathy. Muscle Nerve. (2007) 36(4):411–23. 10.1002/mus.20821 - DOI - PubMed
    1. Gentile L, Coelho T, Dispenzieri A, Conceicao I, Waddington-Cruz M, Kristen A, et al. A 15-year consolidated overview of data in over 6000 patients from the transthyretin amyloidosis outcomes survey (THAOS). Orphanet J Rare Dis. (2023) 18(1):350. 10.1186/s13023-023-02962-5 - DOI - PMC - PubMed
    1. Grogan M, Scott CG, Kyle RA, Zeldenrust SR, Gertz MA, Lin G, et al. Natural history of wild-type transthyretin cardiac amyloidosis and risk stratification using a novel staging system. J Am Coll Cardiol. (2016) 68(10):1014–20. 10.1016/j.jacc.2016.06.033 - DOI - PubMed
    1. Yamada T, Takashio S, Arima Y, Nishi M, Morioka M, Hirakawa K, et al. Clinical characteristics and natural history of wild-type transthyretin amyloid cardiomyopathy in Japan. ESC Heart Fail. (2020) 7(5):2829–37. 10.1002/ehf2.12884 - DOI - PMC - PubMed